- Home
- ITRG vs BOLD Comparison
ITRG vs BOLD Comparison
Compare ITRG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITRG | BOLD |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.5M | 25.7M |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ITRG | BOLD |
|---|---|---|
| Price | $2.87 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $5.13 | $4.00 |
| AVG Volume (30 Days) | ★ 3.0M | 61.2K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.39 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.96 |
| 52 Week High | $4.87 | $1.78 |
Technical Indicators
Market Signals| Indicator | ITRG | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 41.70 |
| Support Level | $2.60 | $0.99 |
| Resistance Level | $3.24 | $1.20 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 44.07 | 13.33 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.